Plain-English translation of NCT06793982 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial tests whether platelet rich plasma (PRP)—a treatment made from your own blood—works better than a for reducing hip arthritis pain. About 54 people with moderate hip arthritis will receive either a PRP injection or a steroid injection into their hip joint, and researchers will track which treatment helps more with pain and everyday activities over time.
Platelet rich plasma is becoming more popular for treating hip arthritis, but there isn't enough solid evidence comparing it head-to-head with the steroid injections doctors currently use. This trial aims to fill that gap so patients and doctors can make better treatment choices.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either a platelet rich plasma injection or a into your hip. The injection itself is a one-time procedure done at the study center. After that, you'll report back on your pain levels and how well your hip is functioning at follow-up visits, allowing researchers to compare which treatment worked better for relieving your symptoms.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
LifeBridge Health
Collaborators
Hip Society
Enrollment target
~54 participants
Started
February 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
21 Years – 80 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Martin Gesheff, DHSc
LifeBridge Health
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.